AI-powered contentSome parts of this article are powered by AI.
Share this article
Summary
Oracle (ORCL) rose 1.20% to $131.09 on October 20, 2026, outpacing the Nasdaq Composite by 1.22 percentage points.
Financial media tied the gain to a non-binding agreement with AstraZeneca to explore AI and real-world data in clinical trials and patient care.
GuruFocus noted the deal's commercial terms remain unresolved, and TIKR flags Oracle's higher debt and negative free cash flow.
Gotrade News - Oracle (ORCL) rose 1.20% to close at $131.09 on Tuesday, October 20, 2026, adding $1.55 in the US session. Financial media tied the gain to the day's main Oracle stock news: a non-binding agreement with AstraZeneca to explore how AI and real-world data could support clinical trials and patient care.
ORCL Trading Data
Data
Value
Closing price
$131.09
Change
+$1.55 (+1.20%)
Previous close
$129.59
Open
$128.51
Day range
$127.45 to $134.35
Volume
26.6 million shares
30-day average volume
33.8 million shares
52-week range
$114.50 to $287.19
Market cap
$396.5 billion
Regular-session close on Tuesday, October 20, 2026, 4:00 p.m. New York time. Stock prices: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Indices and the 10-year Treasury yield: Yahoo Finance daily closes for the same date.
Oracle opened at $128.51, below the prior close of $129.59, then traded between $127.45 and $134.35. It settled $3.69 above the session low but below the high, giving back part of its intraday advance into the close.
Volume came to 26.6 million shares, 21.16% below the 33.8 million average, so the advance ran on lighter trading than usual. Oracle outpaced the Nasdaq Composite, which slipped 0.02% to 26,424.82, by 1.22 percentage points, while the S&P 500 added 0.28% to 7,712.57 and the Dow Jones Industrial Average gained 1.02% to 52,495.88. The US 10-year Treasury yield eased 1.9 basis points to 5.12%.
Among other cloud and software names, Microsoft (MSFT) fell 0.31%, Amazon (AMZN) edged up 0.07% and IBM (IBM) rose 2.34%. Even after the session's gain, Oracle closed 54.34% below its 52-week high of $287.19 and 14.53% above its 52-week low of $114.50.
According to Oracle's official release, distributed on PR Newswire on October 20, the company reached a non-binding agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, speed up evidence generation and bring research insights into everyday care.
Initial disease areas could include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases. Oracle chief executive Mike Sicilia said in the release that "some of the most important opportunities for AI are in healthcare."
As reported by GuruFocus, which linked the shares' rise to the pact, the nonbinding arrangement leaves the size, timing and commercial terms of any rollout unresolved, and investors still need deployment milestones and paid commitments before counting the deal in their revenue models.
Also on October 20, per a GuruFocus report on a BNP Paribas survey, Oracle's software spending indicators improved in October after weakening in July, and BNP Paribas analyst Stefan Slowinski said Oracle's trailing three-month spending score rose more than expected.
ORCL Stock Analysis: Supporting Factors and Risks
Supporting Factors
The AstraZeneca agreement takes Oracle's data, cloud and AI work into clinical research, and the companies plan shared governance and agreed outcome measures, according to the release.
In the BNP Paribas survey, Oracle's database services offered through Amazon and Microsoft cloud platforms ranked among the three most sought-after products, and Oracle Cloud Infrastructure and Fusion applications also improved, as reported by GuruFocus.
Per TIKR, revenue rose 30% to $19.3 billion in the August quarter, cloud infrastructure revenue jumped 121% and the contracted backlog hit $664 billion.
Risks
The agreement is non-binding, and GuruFocus noted that its commercial terms are still unresolved.
According to TIKR, Oracle's debt reached $169.1 billion against $37.1 billion of cash by August 2026, and free cash flow was negative $5 billion in the August quarter as capex hit $28.5 billion.
TIKR points to the fiscal second-quarter earnings report in mid-December as the next test for the shares; that timing is an estimate, not a confirmed date.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
Hendrie Saputra holds a Master of Business Administration (MBA) with a concentration in Business Risk & Finance, along with professional experience in finance, marketing, and project management. He is experienced in analyzing market data and developing research-driven business strategies.
